Teltow / Leipzig, February 25, 2022 - In agreement with the Supervisory Board, Dr. Hans-Joachim Simons has resigned from his position as a member of the Executive Board of CO.DON AG with effect from the end of February 28, 2022, in order to pursue new professional responsibilities.
The Supervisory Board of CO.DON AG thanks Dr. Simons for the valuable contributions he has made to the Company's development during his term of office and wishes him luck and success in his future professional tasks. The other member of the Management Board, Mr. Tilmann Bur, will continue to lead the company as sole member of the Management Board after Dr. Simons' departure until further notice.
CO.DON AG develops, produces and distributes autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint that uses only the patient's own cartilage cells ("autologous chondrocytes"). CO.DON's method is currently used in over 200 clinics in Germany and more than 17,000 patients have already been treated. In July 2017 CO.DON AG received central EU marketing authorisation for this product, followed by the marketing authorization for Switzerland in March 2019. At the Leipzig site, CO.DON has built one of the largest facilities for the production of human cells on an industrial scale for in-house and contract manufacturing. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A3E5C08). Executive Board: Tilmann Bur, Dr Achim Simons.
Further information is available from www.codon.de.
Director Corporate Communications
Investor Relations / Public Relations
T: +49 (0)341 99190 330
F: +49 (0)341 99190 309